Teva's 3 Biggest Challenges


Teva Pharmaceuticals is often referred to as the biggest generic drugmaker in the world, and its 2.8% dividend yield can look attractive to investors seeking health care exposure in their portfolio. However, the company is facing many headwinds in the coming years. Its top-selling multiple sclerosis drug Copaxone, for instance, is not a generic product and is facing upcoming roadblocks that could stall the company's growth. In the following video, health care analyst Max Macaluso elaborates on the three biggest challenges Teva is facing today.

The Motley Fool's chief investment officer has selected his No. 1 stock for the next year. Find out which stock it is in the brand-new free report: "The Motley Fool's Top Stock for 2013." Just click here to access the report and find out the name of this under-the-radar company.

The article Teva's 3 Biggest Challenges originally appeared on

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.